This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...
